Providing practical information in an informative format focused on lipid management of ASCVD in the New Era, learners will be provided with important changes in ASCVD guidelines, recognition of elevated triglyceride levels as a target for therapy, a review of clinical trials that recently made a difference in lipid management, practical considerations on using lipid-modifying therapies, and the latest on omega-3 fatty acids for ASCVD.

Learning Objectives:

  • Have greater clarity on implementing the new 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
  • Describe the spectrum of major recent ASCVD randomized cardiovascular outcomes trials
  • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
  • Apply evidence-based guidelines and recent randomized clinical trial evidence to lifestyle and therapeutic approaches for managing patients at high risk of cardiovascular events

Session supported by Amarin Pharma Inc.